PODD Insulet Corporation
fair · 65
Owner-earnings value$74.45
Price$136.13
Margin of safety
-45.3%
Quality gate · 65/100
Median ROIC9.1%
Gross margin71.1%
Net debt / EBITDA0.4x
FCF conversion74%
Share count / yr+0.4%
Profitable years4/4
Moat & management
Owner-earnings inputs
| Owner earnings (TTM) | 265.60M |
| Owner-earnings yield | 2.8% |
| Free-cash-flow yield | 2.8% |
| Growth used (normalized) | 10.0% |
| Market-implied growth (reverse DCF) | 25.0% |
| Terminal growth | 3.0% |
| Discount rate (hurdle) | 10.0% |
Projected owner earnings
| Yr | Owner earnings | Growth | PV |
|---|---|---|---|
| 1 | 292.16M | 10.0% | 265.50M |
| 2 | 319.10M | 9.2% | 263.53M |
| 3 | 346.05M | 8.4% | 259.71M |
| 4 | 372.58M | 7.7% | 254.11M |
| 5 | 398.25M | 6.9% | 246.84M |
| 6 | 422.58M | 6.1% | 238.02M |
| 7 | 445.12M | 5.3% | 227.84M |
| 8 | 465.40M | 4.6% | 216.49M |
| 9 | 482.98M | 3.8% | 204.17M |
| 10 | 497.47M | 3.0% | 191.11M |
Recent news
score · 8 articles
- Insulet (PODD) Stock May Trade At A Discount To Fair Value
- 2 Healthcare Stocks with Impressive Fundamentals and 1 Facing Challenges
- Insulet (PODD) Reworked Its Debt, Is The Stock Still Cheap?
- Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum
- How Is Insulet's Stock Performance Compared to Other Medical Devices Stocks?
- BCSM Exits Insulet Corporation (PODD), Maintains Watchlist Status
- 2 S&P 500 Stocks with Impressive Fundamentals and 1 We Turn Down
- Why Pay More For Stryker When BSX Stock Is On Sale?
⚠ maintenance capex ≈ min(capex, D&A), capped at FCF · Price pays for ~25%/yr owner-earnings growth over 10y (reverse DCF); model credits 10%.